Lowest Price Guaranteed
Slides
315
Last Updated
January 2026
View Count
14860
The global rare kidney diseases market, valued at USD 2.8 billion in 2025, is projected to reach USD 3.3 billion in 2026 and USD 11.6 billion by 2035, representing a CAGR of 15.2% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Kidney diseases are a set of conditions which hinder the kidney’s natural ability to efficiently filter fluid and waste from the blood. These diseases also lower the ability of kidneys to regulate blood pressure and maintain overall fluid balance in the body. In the early stages, these diseases often do not reflect any symptoms, hence making it difficult to diagnose the disease. However, as the waste builds up in body, patients may report symptoms, such as high blood pressure, anemia, poor nutritional health and nerve damage.
In this context, according to the US Centers for Disease Control and Prevention, in 2024, about 35.5 million people in the US were estimated to be suffering from kidney diseases, which accounted for approximately 14% of the overall population in the US. Rare kidney diseases are a subset of kidney diseases, which only affect a small fraction of people worldwide. According to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans. However, according to the European Union, this criteria range is around 5 per 10,000 Europeans.
 |
 |
 |
These diseases primarily affect the filtering units (known as glomeruli), present in the kidneys, which results in the spillage of the protein components and blood into the urine. Considering that these diseases can either be congenital, acquired or inherited in nature, it is highly difficult to identify biomarkers for their diagnosis and treatment. Further, if not treated timely, these conditions ultimately result in kidney failure that can only be managed / treated through dialysis and kidney transplantation. In this context, it is worth noting that, kidney failure due to a rare chronic kidney disease has been observed to be prevalent in at least 3 in 5 children and 1 in 9 adults suffering from kidney diseases.
 |
 |
 |
To address the challenges mentioned above, several promising advancements have been made for the diagnosis and treatment of these very rare kidney diseases. For instance, the emergence of precision medicine (genomic sequencing and personalized therapies) has enabled the targeted treatment of these diseases. Further, the use of big data and machine learning has significantly helped the drug developers and researchers to recruit the correct patient population in clinical trials and identify accurate urinary biomarkers, which help in providing tailored treatment to the patients.
Investment from both public and private sectors is driving research and development in the rare kidney diseases domain, hence fostering innovation and aiding introduction of cutting-edge rare kidney disease therapies. Currently, over $12 billion has already been raised by drug developers engaged in this domain. Further, with growing emphasis on efficient treatment and diagnosis of these rare types of kidney diseases, the market is poised for robust growth, offering significant opportunities for stakeholders in the coming years.
 |
 |
 |
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2040 | |
| Current Market Size | $3.3 Billion | |
| Market Size 2035 | $11.6 Billion | |
| CAGR (Till 2035) | ~15.2% | |
| Target Disease Indications |
|
|
| Type of Molecule |
|
|
| Type of Biologic |
|
|
| Route of Administration |
|
|
| Type of Therapy |
|
|
| Key Geographical Regions |
|
|
| Leading Drug Developers |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 10% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current rare kidney diseases market size, opportunity and the future growth potential over the forecast period. Based on multiple parameters and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2040.
The market report also features the likely distribution of the current and forecasted opportunity across various segments, such as target disease indication (atypical hemolytic uremic syndrome, Fabry disease, focal segmental glomerulosclerosis, immunoglobulin A nephropathy, lupus nephritis and others), type of molecule (biologics and small molecules), type of biologic (enzymes, hormones, monoclonal antibodies and proteins), route of administration (intravenous, oral and subcutaneous), type of therapy (monotherapy and combination therapy), key geographical regions ((North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia-Pacific (Australia, China, India, Japan, South Korea and Taiwan)), sales forecast and leading drug developers.
In order to account for future uncertainties and to add robustness to our model, we have provided three rare kidney diseases market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders.
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
The global rare kidney diseases market is segmented into various target disease indications, such as atypical hemolytic uremic syndrome, Fabry disease, focal segmental glomerulosclerosis, immunoglobulin A nephropathy, lupus nephritis and others. Currently, the market for lupus nephritis occupies the largest share (~30%) and is expected to remain dominant during the forecast period. This can be attributed to the growing awareness among patients and healthcare professionals about the adversity of the disease. Further, the market for other indications is estimated to grow at a higher CAGR in the coming decade.
This segment highlights the distribution of the rare kidney diseases market across different type of molecules, such as biologics and small molecules. Currently, the small molecules segment captures the highest share (~55%) of the overall market owing to their proven efficacy, ease of administration, lower production costs, accessibility and established safe drug profiles. Examples of small molecule drugs approved for the treatment of immunoglobulin A nephropathy (in alphabetical order) include Filspari® and Tarpeyo®.
However, the landscape is likely to evolve as biologics emerge as a promising and more effective alternative that can target the underlying biological pathways associated with rare kidney diseases. As a result, it is anticipated that biologics will capture a larger market share in the coming years. Notably, Ultomiris® (developed by Alexion Pharmaceuticals) is a biologic blockbuster drug that is currently approved for the treatment of atypical hemolytic uremic syndrome.
This segment highlights the distribution of the rare kidney diseases market across different types of biologics, such as enzymes, hormones, monoclonal antibodies and proteins. Owing to their high target specificity and proven precision to treat rare kidney indications, the monoclonal antibodies segment currently occupies the largest share (85%) in the market and is expected to remain dominant during the forecast period.
The global market is segmented into intravenous, oral, subcutaneous routes of administration. According to our projections, oral route captures the majority rare kidney diseases market share (~55%) owing to its non-invasive nature, convenience of drug administration and increased patient compliance as compared to other routes. This trend is likely to change in the upcoming future with subcutaneous route of administration occupying the greater market share (~30%).
The rare kidney diseases market is categorized into monotherapy and combination therapy. The segment for monotherapy currently occupies a greater share of the market. However, combination therapy is expected to be a new standard of care for patients suffering from rare chronic kidney diseases as it reduces the risk of kidney failure. Due to this, combination therapy segment is anticipated to grow at a higher CAGR (92%) in the coming years.
This segment highlights the distribution of market opportunity across key geographical regions, including North America (US and Canada), Europe (France, Germany, Italy, Spain and UK) and Asia-Pacific (Australia, China, Japan, South Korea, India and Taiwan). It is worth highlighting that North America captures majority of the current total rare kidney diseases market share.
Further, market in Asia-Pacific is expected to grow at a faster pace during the forecast period. This can be attributed to the fact that Asian countries, including China, Japan, Korea and India have a growing incidence rate for rare kidney diseases, and thus require a more effective treatment management system.
The “Rare Kidney Diseases Market (3rd Edition): Industry Trends and Global Forecasts, till 2040” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the rare kidney disease drug developers. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biotechnology and pharmaceutical industry. Key takeaways of the market data analysis are briefly discussed below.
The market landscape is concentrated with the presence of around 110 rare kidney disease drug developers (very large, large, mid-sized and small companies). Of these, 45% of the companies have been established post-2010, indicating significant start-up activity in the rare kidney diseases industry. Examples of companies (established post- 2019, in alphabetical order) include ACELYRIN, APIE Therapeutics, Biohaven, Papillon Therapeutics, TJ Biopharma and Travere Therapeutics.
Notably, around 75% of the drugs developed for rare kidney indications are currently in clinical stages of development, with close to 30% therapies being evaluated in phase III. Further, majority of the drugs developed in the rare kidney diseases domain are biologics. This can be attributed to the fact that they can effectively treat rare autoimmune kidney diseases by specifically targeting the immune system and reducing inflammation in the kidneys to prevent further damage.
The rare kidney disease drug developers have inked several partnerships with stakeholders engaged in this domain in order to enhance their drug portfolios. The growing need for rare kidney disease drugs is evident from the rise in partnership activity in the market. It is worth highlighting that a significant partnership activity has been witnessed in 2023, wherein majority of the deals were inked by industry players headquartered in the US.
Further, close to 15% of deals were signed in 2024, most of these were mergers and acquisitions. This can be attributed to the incessant efforts of stakeholders to further advance their current drug portfolio and initiate development of these drugs across different phases of preclinical and clinical development. Such partnerships are expected to drive the rare kidney diseases market growth during the forecast period.
A cumulative amount of around USD 12 billion has been raised in the rare kidney diseases domain since 2019. This is reflective of the growing interest of players engaged in the development of rare kidney disease drugs, worldwide. It is worth noting that in terms of the funding amount raised, Apellis Pharmaceuticals raised the maximum funding amount worth USD 2,681 million.
Notable examples of funding / investments reported in 2024 include (in reverse chronological order) secondary offerings raised by Travere Therapeutics (November 2024), Vera Therapeutics (October 2024) and Biohaven (October 2024). It is worth mentioning that foreseeing the growing need for the development of novel molecules for rare kidney indications, several companies are poised to invest in different funding rounds, thereby propelling the growth of this industry.
Close to 245 active and completed clinical trials investigating interventions for various rare kidney diseases have been reported since 2019, indicating the substantial research efforts being made in this industry. Further, around 30% clinical trials have been registered in 2024 alone, demonstrating rising awareness amongst researchers and drug developers to develop innovative and novel modalities for the treatment of rare kidney indications.
Additionally, majority of the overall clinical trials observed in the rare kidney diseases domain have already been completed / are under progress in the Asia-Pacific region. This reflects a rapid increase in research activity within this region. Further, owing to a lower infrastructure cost and huge patient pool of untreated population, Asia-Pacific is perceived to be an attractive trial destination for several drug developers, sponsors and principal investigators.
As the next generation of rare kidney disease drugs moves along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.
The global market opportunity for rare kidney disease drugs targeting lupus nephritis is estimated to be around $1.0 billion in the current year and is anticipated to grow at CAGR of 11% during the forecast period. The market growth is primarily fueled by growing awareness among patients and healthcare professionals about the adversity of the disease.
Further, considering the severity of disease, regulatory bodies are actively granting various drug designations, such as fast-track designation and orphan designation to drugs developed for the treatment of lupus nephritis, which is resulting in their early approvals in the market. This has led to the generation of higher revenues for this indication. Examples of approved drugs which have received orphan drug designation by the USFDA (in alphabetical order) include Lupkynis® (developed by Aurinia Pharmaceuticals), Mizoribine (developed by Asahi Kasei) and Myfortic (developed by Novartis).
Currently, North America is anticipated to capture majority of the market share of the global rare kidney diseases market. In recent years, demand for rare kidney disease drugs has witnessed a tremendous increase in North America. Additionally, the advanced healthcare infrastructure in North America enables drug companies to conduct extensive clinical trials required to meet the stringent regulatory guidelines. Further, the market in Asia-Pacific is likely to grow at a higher CAGR in the coming years.
Examples of key developers involved in the rare kidney diseases industry (which have also been captured in this market report, arranged in alphabetical order) include Advicenne Alexion Pharmaceuticals, Amgen, Asahi Kasei, Biogen , Boehringer Ingelheim, Calliditas Therapeutics, Jiangsu Hengrui Pharmaceuticals, Novartis, NovelMed, Roche , Travere Therapeutics, Vertex Pharmaceuticals, Vera Therapeutics and ZyVersa Therapeutics.
This market report includes an easily searchable excel database of all the developers involved in the development of rare kidney disease drugs.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:
Several recent developments have taken place in the field of rare kidney diseases. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our rare kidney diseases market analysis.